Lomax and Trounson reply:
Our 2013 Correspondence 1 focuses on the "imbalance between the potential supply of embryos and the ability to use them in research. " It is motivated by our frequent interaction with prospective embryo donors who aspire to contribute to stem cell research. We emphasize specific remedies to enhance the efficacy of the informed consent process.
We illustrate the imbalance with an updated estimate of the number of embryos stored in the United States. Both we and Snow, Cattapan and Baylis 2 acknowledge that assumptions underpinning our method are inherently conservative, such that our estimate of "more than 1 million" is likely low. By way of comparison, at the end of 2011, 839,325 embryos were in storage in the UK 3 , where the Human Fertilisation and Embryology Authority collects data on human embryos.
Snow, Cattapan and Baylis provide cogent corrections and methodological insights to improve data consistency. However, precisely quantifying the number of stored embryos is secondary to our main argument concerning the ethics and policy imperative-that we must explicitly inform donors about the limited ability to use surplus embryos in stem cell research. Lomax and Trounson 1 note that 1.39 million embryos is likely an underestimate for several reasons. An important one is that "the majority of women undergoing ART procedures do not become pregnant and may discontinue treatment, leaving additional cryopreserved embryos in storage" 1 .
Therefore, it would be more accurate to use not the number of live-birth deliveries but the number of fresh nondonor and donor embryo transfers, which for 2004-2012 was 823,284 (Supplementary Table 2 ). If we assume five stored embryos for each transferred embryo, the total would be 4,116,420-about threefold higher than 1.39 million. To be clear, we are not proposing this number as a correction to 1.39 million given the methodological difficulties of generating this estimate.
Lomax and Trounson 1 acknowledge some but not all of these difficulties. Their assumption of five stored embryos per live delivery is based solely on data from eight northern California clinics (whose actual rate was seven embryos per live delivery) 10 , which may not hold nationally. And although they note that "improvements in ART pregnancy success rates may have resulted in a higher proportion of unused embryos, " 1 they do not mention other changes in ART practice since 2003 that may be relevant. For example, the move to embryo transfer at the blastocyst stage may have decreased the proportion of stored embryos to live-birth deliveries 11 , whereas wider use of single-embryo transfer and improved freezing technology may have increased it.
These issues highlight the need for empirical research on the number of cryopreserved embryos in the United States and elsewhere to provide a sound basis on which to develop guidelines, policies and laws governing both ART treatment and embryo research.
